Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilostazol.

J W Cheng1

  • 1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA.

Heart Disease (Hagerstown, Md.)
|November 27, 2001
PubMed
Summary
This summary is machine-generated.

Cilostazol effectively treats intermittent claudication by inhibiting phosphodiesterase III. However, it is not recommended for patients with severe heart failure due to potential risks observed in similar medications.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Investigation and analysis of underground noise in Sichuan coal mines].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2022
Same author

[Association between a novel regulatory genetic variants and lung cancer risk in Chinese: a two-stage case-control study].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2021
Same author

[Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2020
Same author

[Focus on the controversial problems of orbital decompression in the treatment of dysthyroid optic neuropathy].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2018
Same author

Synthesis, dual-nonlinear magnetic resonance and microwave absorption properties of nanosheet hierarchical cobalt particles.

Physical chemistry chemical physics : PCCP·2014
Same author

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Journal of clinical pharmacy and therapeutics·2014
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Area of Science:

  • Pharmacology
  • Vascular Medicine

Background:

  • Intermittent claudication is a common symptom of peripheral artery disease.
  • Phosphodiesterase III inhibitors offer a therapeutic option for managing this condition.

Purpose of the Study:

  • To evaluate the efficacy and safety of cilostazol for symptomatic intermittent claudication.

Main Methods:

  • Review of existing clinical studies and pharmacological data on cilostazol.
  • Analysis of contraindications and potential adverse effects.

Main Results:

  • Cilostazol demonstrates effectiveness in improving symptoms of intermittent claudication.
  • The drug is generally well-tolerated.
  • Contraindicated in patients with severe heart failure due to class-related risks.

Conclusions:

  • Cilostazol is a viable treatment for intermittent claudication.
  • Further research is needed to ascertain long-term benefits and safety profiles.